Biaxin

Cat-Scratch Disease, Sinusitis, Whooping Cough + 14 more

Treatment

21 FDA approvals

20 Active Studies for Biaxin

What is Biaxin

Clarithromycin

The Generic name of this drug

Treatment Summary

Clarithromycin is an antibiotic used to treat bacterial infections. It works by preventing bacteria from producing proteins which are necessary for their growth and survival. Clarithromycin can either stop the bacteria from multiplying or kill them, depending on the concentration of the drug and the type of bacteria.

Biaxin

is the brand name

image of different drug pills on a surface

Biaxin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Biaxin

Clarithromycin

1991

187

Approved as Treatment by the FDA

Clarithromycin, also known as Biaxin, is approved by the FDA for 21 uses which include Acute maxillary sinusitis and Bacterial Infections .

Acute maxillary sinusitis

Bacterial Infections

Otitis Media (OM)

Mycobacterial Infections

uncomplicated skin and subcutaneous tissue bacterial infections

prophylaxis of Mycobacterial infection

Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)

Duodenal ulcer caused by helicobacter pylori

Used to treat Duodenal ulcer caused by helicobacter pylori in combination with Amoxicillin

Tonsillitis streptococcal

Streptococcal Pharyngitis

Bronchitis, Chronic

Urinary Tract Infection (UTI)

HIV

Otitis

Duodenal Ulcer

Used to treat Duodenal ulcer caused by helicobacter pylori in combination with Amoxicillin

Mycobacterium Infections

Sinusitis

Community Acquired Pneumonia (CAP)

Bacterial Infections

Tuberculosis

Tonsillitis

Effectiveness

How Biaxin Affects Patients

Clarithromycin is an antibiotic that is effective against many types of bacteria, including those that cause pneumonia, ear infections, and other types of infections. It works by either stopping the bacteria from growing or killing them. Clarithromycin is usually more effective than erythromycin at treating bacterial infections.

How Biaxin works in the body

Clarithromycin works by entering bacteria cells and binding to the ribosome, preventing the bacteria from making proteins. It also inhibits an enzyme in the liver, as well as an energy-dependent pump that helps remove drugs from the body. This combination of effects makes it difficult for bacteria to survive and reproduce.

When to interrupt dosage

The advised measure of Biaxin is contingent upon the diagnosed condition, such as Mycobacterium Infections, Lyme Disease and Bacterial Infections. The amount of dosage is contingent upon the method of delivery (e.g. Powder, for suspension or Capsule; Kit; Tablet) outlined in the table below.

Condition

Dosage

Administration

Mycobacterium Infections

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Bacterial Infections

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Tuberculosis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Bacterial Endocarditis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Duodenal Ulcer

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

HIV

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Bronchitis, Chronic

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Bacterial Endocarditis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Community Acquired Pneumonia (CAP)

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Streptococcal Pharyngitis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Cat-Scratch Disease

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Sinusitis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Whooping Cough

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Lyme Disease

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Urinary Tract Infection (UTI)

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Tonsillitis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Otitis

, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg

, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Warnings

Biaxin Contraindications

Condition

Risk Level

Notes

Liver Dysfunction

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Jaundice, Obstructive

Do Not Combine

There are 20 known major drug interactions with Biaxin.

Common Biaxin Drug Interactions

Drug Name

Risk Level

Description

(R)-warfarin

Major

The metabolism of (R)-warfarin can be decreased when combined with Clarithromycin.

(S)-Warfarin

Major

The metabolism of (S)-Warfarin can be decreased when combined with Clarithromycin.

1,2-Benzodiazepine

Major

The metabolism of 1,2-Benzodiazepine can be decreased when combined with Clarithromycin.

3,5-diiodothyropropionic acid

Major

The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Clarithromycin.

5-androstenedione

Major

The metabolism of 5-androstenedione can be decreased when combined with Clarithromycin.

Biaxin Toxicity & Overdose Risk

Taking too much clarithromycin can cause diarrhea, nausea, changes in taste, indigestion, abdominal pain, temporary hearing loss, and allergic reactions such as hives and rashes. Rare cases of severe liver damage, pseudomembraneous colitis, Stevens-Johnson syndrome, and anaphylaxis have also occurred. In addition, clarithromycin may cause tooth discoloration and fetal abnormalities in animals. It can also cause changes in the electrical activity of the heart that can lead to QT prolongation.

image of a doctor in a lab doing drug, clinical research

Biaxin Novel Uses: Which Conditions Have a Clinical Trial Featuring Biaxin?

160 active clinical trials are currently underway to assess the potential of Biaxin to address Pertussis, HIV and Urinary Tract Infection (UTI).

Condition

Clinical Trials

Trial Phases

Mycobacterium Infections

0 Actively Recruiting

Whooping Cough

0 Actively Recruiting

HIV

155 Actively Recruiting

Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1

Urinary Tract Infection (UTI)

6 Actively Recruiting

Phase 1, Phase 3, Phase 4, Phase 2

Streptococcal Pharyngitis

0 Actively Recruiting

Tonsillitis

0 Actively Recruiting

Community Acquired Pneumonia (CAP)

5 Actively Recruiting

Not Applicable, Phase 1, Phase 3

Otitis

0 Actively Recruiting

Cat-Scratch Disease

0 Actively Recruiting

Sinusitis

0 Actively Recruiting

Bronchitis, Chronic

0 Actively Recruiting

Bacterial Infections

0 Actively Recruiting

Bacterial Endocarditis

1 Actively Recruiting

Not Applicable

Duodenal Ulcer

0 Actively Recruiting

Bacterial Endocarditis

0 Actively Recruiting

Tuberculosis

0 Actively Recruiting

Lyme Disease

3 Actively Recruiting

Phase 1, Phase 2, Phase 3, Not Applicable

Biaxin Reviews: What are patients saying about Biaxin?

5

Patient Review

6/8/2014

Biaxin for Bacterial Infection with Chronic Bronchitis

I've had chronic bronchitis for a while now, and this is the only medication that's been effective in treating it. It works quickly to stop bacteria growth, which is great. The only downside is that it can cause a weird taste in your mouth. other than that, though, I highly recommend it!

5

Patient Review

2/18/2014

Biaxin for Acute Infection of the Nose, Throat or Sinus

I'm on my last day of taking this drug and, while it's been effective, the side effects have really made me question why I was prescribed it in the first place. The taste it leaves in your mouth is gross, and it kills your appetite. In addition, I've had trouble sleeping and constantly racing thoughts.

5

Patient Review

1/11/2020

Biaxin for infection caused by bacteria

I started feeling better very quickly after beginning this medication, and I'm now having really vivid dreams. The only downside is that sometimes I get a bad taste in my mouth at night, but it's not a big issue.

4.3

Patient Review

12/6/2015

Biaxin for Acute Inflammation of the Maxillary Sinus

The metallic taste can be a bit off-putting, but it's manageable. I had no issues with appetite or stomach pain. Headaches were mild and may not have been caused by the drug. By day five, I was feeling much better--though my symptoms weren't completely gone.

4

Patient Review

1/31/2018

Biaxin for Bacterial Pneumonia caused by Haemophilus Influenzae

I was warned by my doctor about the metallic taste, but he also provided a solution: take the pill with root beer! I tried it and it worked great.

4

Patient Review

3/26/2015

Biaxin for Acute Infection of the Nose, Throat or Sinus

This medicine gave me some bad stomach cramps and diarrhea. I found that it helped to take it at the end of a meal instead of with my meal.

3.7

Patient Review

5/11/2014

Biaxin for Mycobacterium Avium Bacteria Infection

I've been on Biaxin for two weeks now, and I haven't experienced the same negative side effects that many users have reported. I just started my second round of medication, and I'll be adding a third next week. I'm looking at a year of intensive antibiotic treatment, but so far it's been going well. I'm taking supplements, probiotics, and checking in with my medical team regularly. I know there will be side effects down the road, but I'll deal with them as best as I can. It's too soon to tell if the medication is effective, but I've used it before with success

3.7

Patient Review

11/6/2013

Biaxin for Mycobacterium Avium Bacteria Infection

3

Patient Review

1/16/2014

Biaxin for Acute Infection of the Nose, Throat or Sinus

This medicine caused my lower legs to swell and I found myself tiring more easily. Additionally, I experienced pain in my lower legs.

2.7

Patient Review

7/22/2016

Biaxin for Inflammation of the Stomach Lining caused by H. Pylori

I'm on 500 mg, twice a day. I haven't gotten the metallic taste in my mouth that others have reported, but I have noticed pretty severe nausea and gastric upset. These symptoms are stronger than any other antibiotic I've taken.

1

Patient Review

6/6/2014

Biaxin for Bacterial Infection with Chronic Bronchitis

I had awful stomach cramps and diarrhea. My head was throbbing painfully, and my blood pressure shot up to 172/124. I genuinely thought I was going to have a stroke.

1

Patient Review

8/14/2014

Biaxin for Bronchitis caused by the Bacteria Haemophilus Influenzae

This was a terrible experience. I ended up in the hospital and it felt like a bad trip. The pain was unbearable and it's been a month, and I'm still not feeling any better. This treatment messed me up and I've been having trouble sleeping and panic attacks ever since.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about biaxin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Biaxin the same as amoxicillin?

"Amoxil works to treat bacterial infections while Biaxin is effective in treating most common respiratory infections. Both medications may result in mild side-effects."

Answered by AI

What is the drug Biaxin used for?

"Clarithromycin is an antibiotic used to treat bacterial infections. It can also be used with other medications to treat stomach ulcers, or to prevent certain bacterial infections."

Answered by AI

Is Biaxin penicillin based?

"It is safe to take Biaxin (clarithromycin) if you are allergic to penicillin, as they are in different antibiotic classes."

Answered by AI

Is Biaxin the same as doxycycline?

"Vibramycin (doxycycline) is an effective treatment for many bacterial infections, but it can make your skin more sensitive to sunlight and increase your risk of sunburn or rash. It is a good first-choice treatment for respiratory infections. Biaxin (clarithromycin) is better tolerated than similar medicines."

Answered by AI

Clinical Trials for Biaxin

Image of Alabama CRS (Site ID: 31788) in Birmingham, United States.

Antibodies for HIV

18 - 55
All Sexes
Birmingham, AL

This study is testing a lab-made antibody called ePGT121v1-LS that targets a specific part of HIV. Researchers will give it by vein (IV) and under the skin (SC), both on its own and together with two other antibodies, VRC07-523LS and PGDM1400LS, which target different parts of the virus. They will assess safety and side effects, determine the right dose, study how the body processes the drug (pharmacokinetics or PK), and measure how well it neutralizes HIV in the blood (serum neutralizing activity). The expectation is that ePGT121v1-LS, whether given alone or with PGDM1400LS and VRC07-523LS, by IV or SC, will be safe in generally healthy adults and that the antibodies will not interfere with each other when used together. Approximately 83 volunteers in overall good health and without HIV-1 will be enrolled into two parts (A and B). Part A has six groups. In Groups 1-3, participants will get ePGT121v1-LS given by IV at one of three dose levels: 5 mg/kg, 20 mg/kg, or 40 mg/kg. In Groups 4-6, participants will receive three antibodies-first ePGT121v1-LS, then PGDM1400LS and VRC07-523LS-given by IV at two separate visits that are 24 weeks apart. The total study duration for participants in Part A is 48 weeks of scheduled clinic visits. Part B has two groups. In Group 7, people will get ePGT121v1-LS as SC shots at two visits 12 weeks apart. Each visit will give a total of 375 mg, split into three injections of 125 mg each. In Group 8, people will also have two visits 12 weeks apart and will receive three antibodies as SC shots in this order: first ePGT121v1-LS (125 mg), then PGDM1400LS (100 mg), and then VRC07-523LS (100 mg). The total study duration for participants in Part B is 24 weeks of scheduled clinic visits.

Phase 1
Waitlist Available

Alabama CRS (Site ID: 31788) (+5 Sites)

Image of New Jersey Community Research Initiative in Newark, United States.

AI-DBT for Suicide Prevention in HIV/AIDS

18+
All Sexes
Newark, NJ

One in four older persons living with HIV/AIDS (PLWHA) report at least one suicide attempt in their lifetime, and the risk for death by suicide is 100 times higher in PLWHA than in the general population. Currently, there are no behavioral interventions that specifically address suicide prevention for older PLWHA, despite their unique biopsychosocial and structural risk factors. Through this work, investigators will adapt Dialectical Behavior Therapy, an evidence-based intervention for suicide prevention, for patients with PLWHA to be delivered by an AI-powered conversational Agent developed by our industry partner, Empower Health. Investigators will then pilot test the feasibility, usability, acceptability and preliminary efficacy to improve self-efficacy to manage negative emotions in n=50 older adults living with HIV/AIDS.

Recruiting
Has No Placebo

New Jersey Community Research Initiative (+1 Sites)

Elissa Kozlov, PhD

Image of George Washington University Emergency Department in Washington D.C., United States.

Decision Support Tool for HIV Prevention

18+
All Sexes
Washington D.C., United States

This project will explore the development of a personalized decision support tool to assist with pre-exposure prophylaxis (PrEP) initiation and persistence among patients identified in the emergency department (ED) and urgent care settings as PrEP eligible. First, the investigators will use a sequence of validated implementation science methodologies to develop and validate a decision support tool designed to optimize PrEP persistence by strengthening self-efficacy by addressing the multifaceted medical and social needs of the individual patient. The investigators will then test the preliminary effectiveness of this tool through a pilot stepped wedge implementation trial in two EDs and an urgent care in Baltimore, MD and Washington, DC among 120 PrEP eligible patients to determine PrEP initiation, linkage to care, persistence, and adherence rates.

Phase 1
Waitlist Available

George Washington University Emergency Department (+1 Sites)

Have you considered Biaxin clinical trials?

We made a collection of clinical trials featuring Biaxin, we think they might fit your search criteria.
Go to Trials
Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL

The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.

Phase < 1
Waitlist Available

University of Alabama at Birmingham

Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA

This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.

Waitlist Available
Has No Placebo

Los Angeles General Medical Center

Hayoun Lee, PhD

Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC

This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.

Phase 1
Recruiting

University of North Carolina

Cynthia L. Gay, MD

Have you considered Biaxin clinical trials?

We made a collection of clinical trials featuring Biaxin, we think they might fit your search criteria.
Go to Trials

Have you considered Biaxin clinical trials?

We made a collection of clinical trials featuring Biaxin, we think they might fit your search criteria.
Go to Trials